price month
 close
recent visit charl river laboratori facil wilmington
met todd spencer vice-president investor relat leader across
rad busi unit rm segment revenu
sustain price increas per year forese futur
continu off-set on-going rm volum pressur rm slate
growth lsd lt sustain oper margin leverag
leadership posit rodent model boast industri
advanc biosecur technolog system well faster
grow servic offer make chang
estim rais tp walk away
meet increment construct lt growth prospect
remain strong emphas better posit vs histor
relat potenti market cyclic across increasingli divers
platform note track multipl data point measur health
biotech fund environ accord bioworld biotech fund
increas ytd support crl view one
strongest fund year also highlight small mid-siz biopharma
compani grow faster top global biopharma
compani year cash biotech balanc sheet
 mainstay spent billion acquisit sinc
strateg remain meaning compon growth
strategi deal sinc repres one-third revenu note
robust acquisit pipelin less competit market opportun
across three segment less interest augment
research model busi express interest bolster rm
servic capabl also highlight ampl opportun
view larger deal less like nt given lofti valuat
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price sep rate neutral target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
charl river laboratori intern inc full servic earli
model research develop new drug devic
blue sky scenario assum continu
robust industri trend expedit pronounc synergi
recent acquisit near term acceler larg pharma
biotech demand consist price increas identif
greater margin expans opportun continu market share
grey sky scenario assum oper
disrupt miscu recent acquisit weak
pressur increas insourc competit
 close
rm strive lsd revenu growth oper margin
notabl maintain stabl market share address market
continu maintain high price visibl per year potenti
opportun push price higher given import rel low cost
model remind volum remain pressur given biopharma industri
consolid well better complex model drive need fewer overal
model expect flat slightli lower volum growth western matur
market partial off-set robust dd growth china revenu
highlight china manag expect china crl largest research model
market unit volum attribut region strength oversimplif
chines competitor scientif requir research model note crl
current market share chines model market reach
figur revenu mix segment
genet engin model servic facil wilmington hous
mice mous model given time remain
model rat-bas model laboratori essenti own
client project run short three month long year
client util mani unit units/box facil
model mous run cheap major mice
common mous subtyp other may cost multipl hundr dollar
 obes rat diabet studi
model also oper isol ventil technolog includ intak
outtak valv protect control environ contamin
biosecur system offer point differenti competitor still primarili util
histor model monitor manual paper-bas system
implement internet coloni manag icm system cage
within model tag rfid sensor today technician carri
tablet scanner track activ monitor model real-tim moreov
client may also receiv real-tim updat crl mypreclin portal
hope build on-line order system platform
remind offer quarantin servic product breed anim hold
ivf coloni expans max-bax speed congen quick coloni start-up mous
rescu packag recoveri mous line longer produc offspr
research anim diagnost servic rad facil oper sinc
maintain qualiti control model includ product model
model made well client model includ local lab lab
numer locat time scope test vari gener dictat
project protocol busi unit current sit squar foot facil util
capac remaind use storag excess capac could renov
expand rad offer
among servic rad conduct polymeras chain reaction pcr test
emphas thermo chip technolog emb proprietari assay
averag day turnaround time specif highlight exhaust air dust
pcr test capabl launch two year ago determin health
entir model one swab model air filter pcr volum higher
serolog high capital-expenditure requir drive profit serolog
common test offer importantli name idexx radil bioanalyt offer
largest competitor rodent test bioallianc viral refer lab vrl also
competitor space
note bacteriolog lab agnost equip manufactur seek
innov technolog also util proprietari accugenix data platform
acquir remind accugenix provid cgmp-compliant contract
microbi identif test leader species-level identif
strain type bacteria fungi recov manufactur facil
bacteriolog lab come across unidentifi sampl send sampl direct
accugenix analyz identifi add strain databas
new rad due increas demand recent expand microbiom
servic test new dedic space facil greater industri focu
bacteri gi associ behavior trial autism
safeti assess updat safeti repres dsa expect grow hsd
segment overal growth rate close align safeti
current safeti outsourc penetr ten year ago
expect expand rang importantli view
safeti outsourc penetr ever reach client like requir
capabl in-hous particularli relat interpret result fda review
space
client
awareness/tract still build view busi could grow fast
faster safeti assess lt cross-sel expect reach vs
today discoveri work outsourc today view penetr
reach somewher around outsourc provid ampl runway futur
mpi ahead remain confid mpi acquisit note integr
ahead plan note includ mpi wil maintain market share
billion outsourc safeti assess market maintain optim capac
level excess capac squar foot facil offer room mpi
margin leverag expect maintain slightli improv rm margin
rang view dsa segment largest margin opportun
expect reach rang overal margin declin follow wil
acquisit manag highlight reason wil mpi couldnt
achiev margin legaci dsa previous announc wage increas
broadli implement made chang assumpt front
track multipl data point measur health biotech fund environ
accord bioworld comprehens data sourc biotech fund includ
public privat sourc declin august albeit difficult comp y/i
august heel juli latest data suggest
fund promis molecul biotech balanc sheet remain healthi
bode well fundament demand across cro univers caveat emphas
fund stem multipl sourc may fulli repres data
instanc larg pharmaceut compani repres key sourc fund
small mid-siz biotech compani inher insul broader capit
market activ ventur capit public market fund importantli
emphas better posit relat market cyclic highlight
era perfect storm tougher macro pipelin environ
figur quarterli overal biotech fund includ public offer fund public
biotechnolog compani fund privat biotechnolog compani
figur monthli overal biotech fund includ public offer fund public biotechnolog
compani fund privat biotechnolog compani
biotechspublic/otherpubl biotechspublic/otherpubl growth charl martineau pm univers toronto figur public offer biotech compani includ ipo follow-on monthli
figur financ public biotechnolog compani monthli
includ loan bridg financ exercis warrant debt offer right offer standard privat placement pipe
financ institut offer regist stock
year-over-year growth growth year-over-year growth year-over-year growth growth charl martineau pm univers toronto figur fund privat biotechnolog compani monthli
figur revenu mix client type
growth year-over-year growth charl martineau pm univers toronto
compani mention price
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
